(+)-Fenfluramine and its major metabolite, (+)-norfenfluramine, are potent substrates for norepinephrine transporters

Journal of Pharmacology and Experimental Therapeutics

Volumn 305, Issue 3, 2003, Pages 1191-1199

  Rothman, Richard B ^a   Clark, Robert D ^a   Partilla, John S ^a   Baumann, Michael H ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DRUG METABOLITE; FENFLURAMINE; NISOXETINE; NORADRENALIN; NORADRENALIN TRANSPORTER; NORFENFLURAMINE; SEROTONIN; TRITIUM;

ANIMAL EXPERIMENT; ARTICLE; DOPAMINE BRAIN LEVEL; DRUG EFFECT; DRUG POTENCY; DRUG PROTEIN BINDING; FRONTAL CORTEX; ISOMER; MALE; MICRODIALYSIS; NONHUMAN; NORADRENALIN BRAIN LEVEL; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; RAT; SEROTONIN BRAIN LEVEL; STEREOISOMERISM; SYNAPTOSOME;

ANIMALS; BIOGENIC MONOAMINES; FENFLURAMINE; MALE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; NORFENFLURAMINE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SYMPORTERS; TRITIUM;

EID: 0038137478     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.049684     Document Type: Article

References (43)

1. Andersson B, Zimmermann ME, Hedner T, and Bjorntorp P (1991) Haemodynamic, metabolic and endocrine effects of short-term dexfenfluramine treatment in young, obese women. Eur J Clin Pharmacol 40:249-254.
2. Baumann MH, Ayestas MA, Dersch CM, and Rothman RB (2001) 1-(m-Chloraphenyl)piperazine (mCPP) dissociates in vivo serotonin release from long-term serotonin depletion in rat brain. Neuropsychopharmacology 24:492-501.
3. Caccia S, Conforti I, Duchier J, and Garattini S (1985) Pharmacokineties of fenfluramine and norfenfluramine in volunteers given D- and DL-fenfluramine for 15 days, Eur J Clin Pharmacol 29:221-224.
4. Carboni E, Tanda GL, Frau R, and Di Chiara G (1990) Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem 55:1067-1070.
5. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
6. 19F magnetic resonance spectroscopy. Brain Res 834:1-5.
7. Cody RJ (1997) The sympathetic nervous system and the renin-angiotensinaldosterone system in cardiovascular disease. Am J Cardiol 80:9J-14J.
8. Connolly HM and McGoon MD (1999) Obesity drugs and the heart. Curr Probl Cardiol 24:745-792.
9. Cozzi NV, Frescas S, Marona-Lewicka D, Huang X, and Nichols DE (1998) Indan analogs of fenfluramine and norfenfluramine have reduced neurotoxic potential. Pharmacol Biochem Behav 59:709-715.
10. Curzon G, Gibson EL, and Oluyomi AO (1997) Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability. Trends Pharmacol Sci 18:21-25.
11. De Souza EB, Zaczek R, Culp S, Appel NM, and Contrera JF (1991) Comparison of the effects of repeated oral versus subcutaneous fenfluramine administration on rat brain monoamine neurons: pharmacokinetic and dose-response data. Pharmacol Biochem Behav 39:963-969.
12. 2B receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 57:75-81.
13. Flechtner-Mors M, Ditschuneit HH, Yip I, and Adler G (1998) Blood pressure and plasma norepinephrine responses to dexfenfluramine in obese postmenopausal women. Am J Clin Nutr 67:611-615.
14. Garattini S (1995) Biological actions of drugs affecting serotonin and eating. Obes Res 3 (Suppl 4):463S-470S.
15. Garattini S, Mennini T, Bendotti C, Invernizzi R, and Samanin R (1986) Neurochemical mechanism of action of drugs which modify feeding via the serotoninergic system. Appetite 7 (Suppl):15-38.
16. Gibson EL, Kennedy AJ, and Curzon G (1993) d-Fenfluramine- and d-norfenfluramine-induced hypophagia: differential mechanisms and involvement of postsynaptic 5-HT receptors. Eur J Pharmacol 242:83-90.
17. Gundlah C, Martin KF, Heal DJ, and Auerbach SB (1997) In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor. J Pharmacol Exp Ther 283:581-591.
18. Hirsch J, Mackintosh RM, and Aronne LJ (2000) The effects of drugs used to treat obesity on the autonomic nervous system. Obes Res 8:227-233.
19. Itskovitz HD, Werber JL, Sheridan AM, Brewer TF, and Stier CT Jr (1989) 5-Hydroxytryptophan and carbidopa in spontaneously hypertensive rats. J Hypertens 7:311-315.
20. Kolanowski J, Younis LT, Vanbutsele R, and Detry JM (1992) Effect of dexfenfluramine treatment on body weight, blood pressure and noradrenergic activity in obese hypertensive patients [see comments]. Eur J Clin Pharmacol 42:599-605.
21. Launay JM, Herve P, Peoc'h K, Tournois C, Callebert J, Nebigil CG, Etienne N, Drouet L, Humbert M, Simonneau G, et al. (2002) Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 8:1129-1135.
22. Linner L, Endersz H, Ohman D, Bengtsson F, Schalling M, and Svensson TH (2001) Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectively increases dopamine availability in the prefrontal cortex. J Pharmacol Exp Ther 297:540-546.
23. Maestri E, Camellini L, Rossi G, Rossi GP, Dotti C, Marchesi M, and Gnudi A (1988) Serotonin regulation of aldosterone secretion. Horm Metab Res 20:457-459.
24. 14C-(±)-fenfluramine in mouse, rat, dog and man. Xenobiotica 22:1251-1266.
25. Oates HF, Stoker LM, MacCarthy EP, Monaghan JC, and Stokes GS (1978) Comparative haemodynamic effects of clonidine and guanfacine. Arch Int Pharmacodyn Ther 231:148-156.
26. Pettersson E (1995) Studies of four novel diphenylbutylpiperazinepyridyl derivatives on release and inhibition of reuptake of dopamine, serotonin and noradrenaline by rat brain in vitro. Eur J Pharmacol 282:131-135.
27. Pinder RM, Brogden RN, Sawyer PR, Speight TM, and Avery GS (1975) Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity. Drugs 10:241-323.
28. Raiteri M, Bonanno G, and Vallebuona F (1995) In vitro and in vivo effects of d-fenfluramine: no apparent relation between 5-hydroxytryptamine release and hypophagia. J Pharmacol Exp Ther 273:643-649.
29. Ramirez AJ, Chemerinski E, and Enero MA (1982) Central serotonergic participation on blood pressure regulation. Gen Pharmacol 13:427-432.
30. Rothman RB, Ayestas MA, Dersch CM, and Baumann MH (1999) Aminorex, fenfluramine and chlorphentermine are serotonin transporter substrates: implications for primary pulmonary hypertension. Circulation 100:869-875.
31. Rothman R and Baumann M (2002) Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol Ther 95:73.
32. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, and Partilla JS (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39:32-41.
33. 2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102:2836-2841.
34. Rothman RB, Lewis B, Dersch CM, Xu H, Radesca L, de Costa BR, Rice KC, Kilburn RB, Akunne HC, and Pert A (1993) Identification of a GBR12935 homolog, LR1111, which is over 4000-fold selective for the dopamine transporter, relative to serotonin and norepinephrine transporters. Synapse 14:34-39.
35. Rudnick G and Clark J (1993) From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters. Biochim Biophys Acta 1144:249-263.
36. Schoeppe W and Brecht HM (1980) Guanfacine in essential hypertension: effect on blood pressure, plasma noradrenaline concentration and plasma renin activity. Br J Clin Pharmacol 10 (Suppl 1):97S-101S.
37. Tanda G, Pontieri FE, Frau R, and Di Chiara G (1997) Contribution of blockade of the noradrenaline carrier to the increase of extracellular dopamine in the rat prefrontal cortex by amphetamine and cocaine. Eur J Neurosci 9:2077-2085.
38. Tao R, Fray A, Aspley S, Brammer R, Heal D, and Auerbach S (2002) Effects on serotonin in rat hypothalamus of D-fenfluramine, aminorex, phentermine and fluoxetine, Eur J Pharmacol 445:69-81.
39. 3H]Nisoxetine: a radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding. J Pharmacol Exp Ther 260:427-436.
40. Van de Kar LD, Richardson Morton KD, and Brownfield MS (1994) Brain catecholamines mediate the delayed reduction in renin release after injection of fenfluramine. Brain Res 634:77-84.
41. 2C receptors. Neuropharmacology 41:200-209.
42. Weiner N (1989) Norepinephrine, epinephrine and the sympathomimetic amines, in Goodman's and Gilman's The Pharmacological Basis of Therapeutics (Gilman AG, Goodman LS, Rall TW and Murad F eds) pp 145-180, MacMillan, New York.
43. Zimmermann H and Ganong WF (1980) Pharmacological evidence that stimulation of central serotonergic pathways increases renin secretion. Neuroendocrinology 30:101-107, 109.